COMUNICADO: New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Addition

 

COMUNICADO: New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Addition

Contador
Publicado 21/04/2017 1:02:26CET

The SHAIPI CDI study investigated the clinical outcomes following hospitalisation of patients with CDI in Scotland. The primary analysis 'Clinical outcomes following hospitalisation with Clostridium difficile' aimed to quantify the impact of CDI on recurrence of CDI, mortality, readmissions to hospital and length of stay, in order to understand the impact of the infection.[4] The second analysis 'Clinical outcomes following community associated and hospital associated Clostridium difficile infection: matched case-control studies' investigated the recurrence of CDI and readmissions to hospital, in both community associated CDI (CA-CDI) and hospital associated CDI (HA-CDI) cases, and mortality and length of stay in CA-CDI cases compared to controls and HA-CDI cases compared to controls.[5] The research was funded by Astellas Pharma EMEA.

About Astellas Pharma EMEA    

Astellas Pharma EMEA operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region. In 2013 Astellas was awarded SCRIP Pharmaceutical Company of the Year in recognition of its commercial success and pipeline development.

References   

1. European Centre for Disease Prevention and Control (ECDC). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011-2012. Stockholm, 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf  (last accessed April 2017).

2. Bauer MP, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011;377:63-73.

3. European Centre for Disease Prevention and Control/European Medicines Agency (ECDC/EMEA). Joint technical report The bacterial challenge: time to react. Stockholm: ECDC / EMEA; 2009. Available from: http://ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf  (last accessed April 2017).

4. Data on file, AI/17/0003/APEL, Astellas Pharma Europe Ltd, April 2017.

5. Data on file, AI/17/0002/APEL, Astellas Pharma Europe Ltd, April 2017.

6. Kuijper EJ, et al. ESCMID study group for Clostridium difficile. Emergence of Clostridium difficile associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2-18.

7. Johnson S, et al. Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials. Clin Infect Dis. 2014;59(3):345-54.

8. Lowy I, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362;3:197-205.

9. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31.

10. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008;359(18):1932-1940.

11. Olsen MA, et al. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2014;1-7.

12. Heimann SM, et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection. 2015:43:707.

13. Barbut F, Petit JC. Epidemiology of Clostridium Difficile Associated Infections. Clin Microbiol Infect. 2001;7:405-10.

14. McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy. 2007;27:1029-39.1.

15. Sunenshine R, McDonald L. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med. 2006;73:187-97.

16. Klingler PJ, et al. Clostridium difficile Infection: Risk Factors, Medical and Surgical Management. Digestive Diseases Anti-infectives. 2000:18:147-160.

17. Donnelly JP et al. Hospital-Onset Clostridium difficile Infection Among Solid Organ Transplant Recipients. J Am Transplantation. 2015:15(11):2970-2977.

18. Mamoon A. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. Journal of antimicrobial chemotherapy. 2012:67 (12):2988-2996.

19. Bell BG. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infectious Diseases. 2014;14:13.

20. Bignardi GE. Risk factors for Clostridium difficile infection. J Hospital Infect. 1998:40:1-15.

21. Louie TJ, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clinical Infectious Diseases. 2012:2:S132-142.

22. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26.

23. Oake N, et al. The effect of hospital acquired Clostridium difficile infection on in-hospital mortality. Arch Intern Med. 2010;1701804-10.

24. Hensgens MP, et al. All-Cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a Multicenter Cohort Study. Clin Infect Dis. 2013;56:1108-16.

25. Bauer MP, et al. European Society of Clinical Microbiology and Infectious Disease (ESCMID): treatment guidance document for Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009;15:1067-79.

26. Scottish Healthcare Associated Infection Prevention Institute. About SHAIPI. Available from: http://www.gla.ac.uk/researchinstitutes/iii/research/researchcentres/sirn/shaipi/welcometoshaipi  (last accessed April 2017).

April 2017

AI/17/0002/CB [https://www.zincmapsastellas.com/Jobs/JobView.aspx?Job.Id=69112 ]

CONTACT: For further information please contact: Josie Fisher, Ruder Finn,jfisher@ruderfinn.co.uk, Tel: +44(0)20-7438-3068; Astellas Pharma EMEAPress Office, Tel: +44(0)7919-302-926

Puede cambiar de noticia usando las flechas del teclado (← →)

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

La actualidad más visitada en EuropaPress logo: La actualidad más vista
Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies